

**Holding statement on Direct Oral Anticoagulants (DOACs) often locally described as  
Novel Oral Anticoagulants (NOACs)**

**Date: 29/05/2020**

The CCG along with NHS providers have received correspondence from NHSE/NHSI Commercial Medical Director dated 27<sup>th</sup> May 2020 requesting the supply of direct oral anticoagulants (DOACs) during COVID-19 in appropriate patients. These are only for patients switching directly from **warfarin** to a DOAC (unless there is a patient specific clinical reason to do otherwise). The letter is specific to the use of **apixaban** and **rivaroxaban** upon reaching an agreed discounted price. Our current local Derbyshire guidance is that edoxaban remains the preferred DOAC for Atrial Fibrillation management.

In view of the NHSE/NHSI letter we are reviewing our position both internally at the CCG and also at the Derbyshire Joint Area Prescribing Committee (JAPC) which involves key local stakeholders, on the 9th June 2020 for a formal decision.

**In this interim period we ask that clinicians are mindful of this statement and where appropriate hold switching patients from warfarin to a NOAC/DOAC unless clinically indicated until further local guidance is issued.**

Yours sincerely



**Dr Steven Lloyd, Executive Medical Director  
NHS Derby and Derbyshire Clinical Commissioning Group**



**Mr Steve Hulme, Director of Medicines Management & Clinical Policies  
NHS Derby and Derbyshire Clinical Commissioning Group**